A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo

BACKGROUND: We investigated the efficacy and safety of 60, 120, or 240 mg of Z-360, which is a highly potent cholecystokinin2-receptor-selective antagonist, combined with gemcitabine in patients with metastatic pancreatic cancer. METHODS: Patients were randomly assigned in a 1:1:1:1 ratio to one of...

詳細記述

保存先:
書誌詳細
出版年:Cancer Chemother Pharmacol
主要な著者: Ueno, Makoto, Li, Chung Pin, Ikeda, Masafumi, Ishii, Hiroshi, Mizuno, Nobumasa, Yamaguchi, Taketo, Ioka, Tatsuya, Oh, Do Youn, Ichikawa, Wataru, Okusaka, Takuji, Matsuyama, Yutaka, Arai, Daichi, Chen, Li Tzong, Park, Young Suk, Furuse, Junji
フォーマット: Artigo
言語:Inglês
出版事項: Springer Berlin Heidelberg 2017
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5532401/
https://ncbi.nlm.nih.gov/pubmed/28634650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3351-4
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料